Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bone ; 81: 733-738, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25865577

ABSTRACT

Multiple dimensions of epigenetic control contribute to regulation of gene expression that governs bone biology and pathology. Once confined to DNA methylation and a limited number of post-translational modifications of histone proteins, the definition of epigenetic mechanisms is expanding to include contributions of non-coding RNAs and mitotic bookmarking, a mechanism for retaining phenotype identity during cell proliferation. Together these different levels of epigenetic control of physiological processes and their perturbations that are associated with compromised gene expression during the onset and progression of disease, have contributed to an unprecedented understanding of the activities (operation) of the genomic landscape. Here, we address general concepts that explain the contribution of epigenetic control to the dynamic regulation of gene expression during eukaryotic transcription. This article is part of a Special Issue entitled Epigenetics and Bone.


Subject(s)
Bone and Bones/pathology , Bone and Bones/physiology , Epigenesis, Genetic , Cell Proliferation , DNA Methylation , Histones/metabolism , Humans , Protein Processing, Post-Translational , RNA, Untranslated/genetics
2.
Cells Tissues Organs ; 189(1-4): 133-7, 2009.
Article in English | MEDLINE | ID: mdl-18728344

ABSTRACT

BMP2 signaling and RUNX2 regulatory pathways converge for transcriptional control of bone formation in vivo. SMAD proteins are recruited to RUNX2 regulatory complexes via an overlapping nuclear matrix targeting signal/Smad interacting domain sequence (391-432) in Runx2. To establish the contribution of RUNX2-SMAD interaction to osteoblastogenesis, we characterized a number of point mutants. Only a triple mutation of amino acids 426-428 (HTY-AAA) results in loss of RUNX2 interactions with either BMP2- or TGF-beta- responsive SMADs and fails to integrate the BMP2/TGF-beta signal on target gene promoters. In a Runx2 null cell reconstitution assay, the HTY mutant did not activate the program of osteoblast differentiation (alkaline phosphatase, collagen type 1, osteopontin, bone sialoprotein and osteocalcin) in response to BMP2 signaling. Thus, subnuclear targeting function and formation of a RUNX2-SMAD osteogenic complex are functionally inseparable. Taken together, these studies provide direct evidence that RUNX2 is essential for execution and completion of BMP2 signaling for osteoblast differentiation.


Subject(s)
Amino Acids/metabolism , Bone Morphogenetic Protein 2/pharmacology , Cell Differentiation/drug effects , Core Binding Factor Alpha 1 Subunit/chemistry , Core Binding Factor Alpha 1 Subunit/metabolism , Osteoblasts/cytology , Smad Proteins/metabolism , Amino Acid Sequence , Animals , HeLa Cells , Humans , Mice , Molecular Sequence Data , Mutant Proteins/metabolism , Nuclear Localization Signals/metabolism , Osteoblasts/drug effects , Osteoblasts/metabolism , Signal Transduction/drug effects , Structure-Activity Relationship , Transforming Growth Factor beta/metabolism
3.
Mol Cell Biol ; 24(20): 8847-61, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15456860

ABSTRACT

Bone-specific transcription of the osteocalcin (OC) gene is regulated principally by the Runx2 transcription factor and is further stimulated in response to 1alpha,25-dihydroxyvitamin D3 via its specific receptor (VDR). The rat OC gene promoter contains three recognition sites for Runx2 (sites A, B, and C). Mutation of sites A and B, which flank the 1alpha,25-dihydroxyvitamin D3-responsive element (VDRE), abolishes 1alpha,25-dihydroxyvitamin D3-dependent enhancement of OC transcription, indicating a tight functional relationship between the VDR and Runx2 factors. In contrast to most of the members of the nuclear receptor family, VDR possesses a very short N-terminal A/B domain, which has led to the suggestion that its N-terminal region does not contribute to transcriptional enhancement. Here, we have combined transient-overexpression, coimmunoprecipitation, in situ colocalization, chromatin immunoprecipitation, and glutathione S-transferase pull-down analyses to demonstrate that in osteoblastic cells expressing OC, VDR interacts directly with Runx2 bound to site B, which is located immediately adjacent to the VDRE. This interaction contributes significantly to 1alpha,25-dihydroxyvitamin D3-dependent enhancement of the OC promoter and requires a region located C terminal to the runt homology DNA binding domain of Runx2 and the N-terminal region of VDR. Together, our results indicate that Runx2 plays a key role in the 1alpha,25-dihydroxyvitamin D3-dependent stimulation of the OC promoter in osteoblastic cells by further stabilizing the interaction of the VDR with the VDRE. These studies demonstrate a novel mechanism for combinatorial control of bone tissue-specific gene expression. This mechanism involves the intersection of two major pathways: Runx2, a "master" transcriptional regulator of osteoblast differentiation, and 1alpha,25-dihydroxyvitamin D3, a hormone that promotes expression of genes associated with these terminally differentiated bone cells.


Subject(s)
DNA-Binding Proteins/metabolism , Gene Expression Regulation , Osteoblasts/physiology , Osteocalcin/genetics , Osteocalcin/metabolism , Receptors, Calcitriol/metabolism , Transcription Factors/metabolism , Vitamin D Response Element , Animals , Binding Sites , Cell Line , Core Binding Factor Alpha 1 Subunit , DNA-Binding Proteins/genetics , Genes, Reporter , Macromolecular Substances , Osteoblasts/cytology , Promoter Regions, Genetic , Protein Structure, Tertiary , Rats , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Transcription Factor AP-2 , Transcription Factors/genetics , Transcription, Genetic , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...